Innate intuition

Why Atlas thinks the time is ripe for an inflammasome-focused company

Atlas Venture is re-upping on the hypothesis that the innate immune system, in particular the inflammasome, is not as intractable as many believe. The firm co-led last week's $27 million series A round for IFM Therapeutics Inc., which is

Read the full 391 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers